Source: Annual Congress 2004 - Mesothelioma and malignant pleural effusions - pollution and cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
G. Hillerdal, J. B. Sorensen, A. Vikstrom (Stockholm, Linkoping, Sweden; Copenhagen, Denmark). Treatment of malignant pleural mesothelioma with caelyx: few responses but good survival. Eur Respir J 2004; 24: Suppl. 48, 3273

Member's Comments

No comment yet.

Related content which might interest you: Is there any advantage of chemotherapy on survival of patients with diffuse malignant pleural mesothelioma? Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003 Chemotherapy for treatment of malignant pleural mesothelioma Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004 Second-line chemotherapy in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002 Malignant pleural mesothelioma (MPM): clinical presentation, complications and survival Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002 Evaluation of response to chemotherapy for malignant pleural mesothelioma and suggestion of a new method Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002 Malignant mesothelioma and chemotherapy: efficacy and influence on survival of patients Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002 Systemic therapy 1 in malignant pleural mesothelioma: chemotherapy Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases Year: 2020 Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients Source: Eur Respir J 2011; 38: 1425-1430 Year: 2011 Bevacizumab-targeted therapy for malignant pleural mesothelioma Source: International Congress 2017 – Malignant pleural effusion management in 2017: a review of recent RCTs Year: 2017 Three dimensional evaluation of chemotherapy response in malign pleural mesothelioma Source: Eur Respir J 2007; 30: Suppl. 51, 754s Year: 2007 Multimodal therapy in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002 Survival time in patients with malignant pleural mesothelioma Source: Annual Congress 2007 - Rare tumours, risk factors and epidemiology in thoracic oncology Year: 2007 Cisplatin/pemetrexed chemotherapy versus palliative care survival in malignant pleural mesothelioma Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018 Malignant pleural mesothelioma clinical aspects and survival in 93 cases Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 Predicting survival in malignant mesothelioma Source: Eur Respir J 2011; 38: 1420-1424 Year: 2011 Malignant pleural mesothelioma: new treatment modalities Source: Annual Congress 2005 - Clinical year in review Year: 2005 Systemic treatment of malignant mesothelioma Source: Eur Respir Mon; 2009: 44: 419–434 Year: 2009 Treatment of malignant pleural mesothelioma: dilemmas Source: Eur Respir J 2005; 26: Suppl. 49, 73s Year: 2005 PET predicts survival in malignant pleural mesothelioma Source: ISSN=ISSN 1810-6838, ISBN=, page=290 Year: 2007 Polychemotherapy experience in pleural mesothelioma with or without pemetrexed Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009